STEPHEN KEITH: Open Payments
NPI 1376878926 · TEXARKANA, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,068 in 113 payments from 16 companies in 2025. Trend: 2023 $2,021 · 2024 $2,089 · 2025 $2,068
Food & beverage: $2,023Education: $45
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 22 | $461 |
| Lilly USA, LLC | 15 | $304 |
| ABBVIE INC. | 21 | $296 |
| Novo Nordisk Inc | 9 | $158 |
| Amgen Inc. | 11 | $148 |
| PFIZER INC. | 9 | $141 |
| Corcept Therapeutics | 3 | $109 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $102 |
| GlaxoSmithKline, LLC. | 6 | $94 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $67 |
Products named: MOUNJARO, FARXIGA, AIRSUPRA, ELIQUIS, VRAYLAR, UBRELVY, Korlym, JARDIANCE.
Industry payments across TX — which companies pay providers there.
